BRAF and colorectal cancer: The disease remained under control for 11 months after the first relapse.<h4>Discussion</h4>In the literature there is strong evidence that melanoma, colorectal cancer, non small cell lung cancer and anaplastic thyroid cancer with BRAF mutations are good targets for BRAF/MEK pathway inhibitors.